Progress of hereditary breast cancer with breast cancer susceptibility gene 1/2 mutations
10.3760/cma.j.cn115355-20220628-00396
- VernacularTitle:乳腺癌易感基因1/2突变的遗传性乳腺癌研究进展
- Author:
Yongmei ZHANG
1
;
Huayi ZHANG
;
Gang GUO
Author Information
1. 内蒙古医科大学附属医院临检中心，呼和浩特 010050
- Keywords:
Breast neoplasms;
Genetic susceptibility;
Breast cancer susceptibility gene;
Poly (adenosine diphosphate-ribose) polymerase inhibitor;
Molecular targeted
- From:
Cancer Research and Clinic
2022;34(12):953-956
- CountryChina
- Language:Chinese
-
Abstract:
Hereditary breast cancer refers to malignant tumors caused by pathogenic germline mutations of breast cancer susceptibility genes (BRCA). At present, it is believed that BRCA1/2 genes are most closely related to the development of hereditary breast cancer. Mutation will lead to loss of normal function, instability of genome, and then lead to tumorigenesis. Especially for those with germline mutations, not only the risk of breast cancer will be greatly increased, but also the probability of ovarian cancer and other cancers will be increased. With the emergence and clinical application of poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors, BRCA1/2 genes have been regarded as new targets for the treatment of breast cancer. This article reviews the latest research of breast cancer with BRCA1/2 gene mutations.
